Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 StudyGiuseppe Di Lorenzo, Sabino De Placido, Sisto Perdonà et al.|European Urology|2008Cited by 128
Neutrophil percentage-to-albumin Ratio Predicts Mortality in Bladder Cancer Patients Treated With Neoadjuvant Chemotherapy Followed By Radical CystectomyMatteo Ferro, Mihai Dorin Vartolomei, Dragoș-Florin Babă et al.|Future Science OA|2021Cited by 79
The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundationLuisella Cianferotti, Maria Luisa Brandi, Francesco Bertoldo et al.|Oncotarget|2017Cited by 74
The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort AnalysisMatteo Ferro, Emanuele Zaffuto, Francesco Del Giudice et al.|Cancers|2021Cited by 33
Advanced Age Impacts Survival After Radical Nephroureterectomy for Upper Tract Urothelial CarcinomaMatteo Ferro, Francesco Soria, Sever Chiujdea et al.|Clinical Genitourinary Cancer|2023Cited by 27